Meta-Analysis Examines Cardiovascular Effects of Diabetes Medications
CHICAGO, Oct. 27, 2008—The diabetes medication metformin may be associated with a lower risk of death from cardiovascular disease, according to a meta-analysis of previously published studies in the October 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. No associations were found between other diabetes medications and beneficial or harmful cardiovascular effects, in part because of insufficient data, the authors note.
"A wide variety of oral diabetes medications are currently available for the treatment of type 2 diabetes mellitus," they write as background information in the article. "With the addition of newer oral therapies to the market in the late 1990s (e.g., thiazolidinediones and meglitinides), it is critical to evaluate how these agents compare with older medications. This is particularly important in light of the expense of many of the newer therapies." The specific effects of these medications on cardiovascular health remains unclear, and recent controversy has surrounded possible cardiac risks associated with one newer drug, rosiglitazone.
Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues performed a meta-analysis of data from 40 clinical trials published on or before Jan. 19, 2006. All the trials assessed the benefits or harms of oral diabetes medications approved for use in the United States, including combinations of therapies commonly prescribed by physicians, and included information about heart attack, stroke or other cardiovascular events. The average age of participants ranged from 52 to 69 and 27 of the studies (68 percent) were less than one year in duration.
"Treatment with metformin hydrochloride was associated with a decreased risk of cardiovascular morality [death] compared with any other oral diabetes agent or placebo; the results for cardiovascular morbidity [illness] and all-cause mortality were similar but not statistically significant," the authors write. "No other significant associations of oral diabetes agents with fatal or non-fatal cardiovascular disease or all-cause mortality were observed. When compared with any other agent or placebo, rosiglitazone was the only diabetes agent associated with an increased risk of cardiovascular morbidity and mortality, but this result was not statistically significant."
Poor quality and inconsistent reporting of cardiovascular data, along with the lack of long-term studies, make it difficult to draw firm conclusions, the authors note. "Our study demonstrates that there have been few trials of oral diabetes therapies that have lasted longer than six months and that reporting of adverse events for cardiovascular disease is poor," they continue.
"There is a critical need for studies of oral diabetes medications with long-term outcomes. The relatively modest differences in blood pressure, cholesterol levels and weight observed after treatment with oral diabetes medications in short-term trials may not translate to changes in long-term cardiovascular risk. Only long-term trials can provide definitive conclusions regarding the comparative efficacy of oral diabetes medications and long-term risks."
(Arch Intern Med. 2008;168:2070-2080. Available to the media pre-embargo at www.jamamedia.org).
Editor's Note: This article is based on research conducted by the Johns Hopkins Evidence-Based Practice Center under a contract with the Agency for Healthcare Research and Quality. This study was also supported by grants from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
EDITORIAL: INNOVATIVE APPROACHES NEEDED TO ENSURE SAFETY OF DIABETES MEDICATIONS
"Selvin et al noted that, when it comes to choosing the safest oral agents, the quality of the data are problematic," writes David M. Nathan, M.D., of Massachusetts General Hospital, Boston, in an accompanying editorial.
"The current approach to assessing the relatively rare but clinically important adverse effects of diabetes management is unsatisfactory," he continues. "The vagaries of meta-analyses make them unreliable. On the other hand, increasing the size and duration of controlled clinical trials to provide adequate statistical power to detect relatively infrequent events would potentially bankrupt the pharmaceutical industry that supports most of the trials and delay the development of new drugs."
New approaches are needed to ensure the safety of drugs without slowing development, Dr. Nathan concludes. "For example, the phased introduction of new medications with uniform, standardized collection of adverse outcome data might identify relatively rare complications before the drugs are used by millions. Similarly, the use of clinical databases may provide an early alert regarding adverse outcomes," he writes. "In the meantime, there are well-established and safe treatments that, if used aggressively, can improve the long-term health of patients with type 2 diabetes."
(Arch Intern Med. 2008;168:2064-2066. Available to the media pre-embargo at www.jamamedia.org).
Editor's Note: Please see the article for additional information, including author contributions and affiliations, financial disclosures, funding and support, etc.
For more information, contact JAMA/Archives media relations at 312/464-JAMA (5262) or e-mail firstname.lastname@example.org.
Media Advisory: To contact Elizabeth Selvin, Ph.D., M.P.H., call Tim Parsons at 410-955-7619. To contact editorialist David M. Nathan, M.D., call Sue McGreevey at 617-724-2764.
Posted: October 2008
Recommended for you